07:00 , Mar 24, 2008 |  BioCentury  |  Finance

Nomura's investments

Nomura's investments Nomura's investments Nomura Phase4 Ventures has invested in at least 25 biotechs since 1999. Usually Nomura's contribution for an initial investment will be some $15-$25 million of the round, although in subsequent rounds...
07:00 , May 23, 2005 |  BioCentury  |  Finance

U.S. investment in Europe

U.S. investment in Europe Company Name Country Raised Investors Arpida Switzerland $67.4 Swissfirst; Temasek Capital; Carnegie Asset Management; CDIB BioScience Ventures; CITA; MVI Medical Venture Investments; Schroder Ventures Life Sciences; Alta Berkeley Associates; Aventic; BioMedinvest;...
07:00 , Apr 18, 2005 |  BioCentury  |  Finance

Ebb & Flow

As the sign says, "objects in the rear view mirror are closer than they appear." On the heels of last week's positive Phase III data for Avastin as first-line therapy for metastatic breast cancer, and...
07:00 , May 17, 2004 |  BioCentury  |  Finance

Ebb & Flow

With 21 U.S. IPOs already floated in the States since last October, European investors have been waiting for the European biotech window to crack open. One could argue talk is still cheap, but many now...
07:00 , May 11, 2004 |  BC Extra  |  Top Story

Arpida raises CHF 51.3M

Infectious disease company Arpida (Basel, Switzerland) raised CHF 51.3 million ($39.4 million) in a series C round co-led by swissfirst and Temasek. Other investors included Carnegie Fund; CDIB Bioscience; CITA; MVI Finance; Schroder ISF; Alta...
07:00 , May 14, 2003 |  BC Extra  |  Financial News

Biomedical Diagnostics raises EUR 9.3M

Biomedical Diagnostics (Marne-la-Vallee, France) raised EUR 9.3 million ($10.7 million) in a private round. Investors included Truffle Venture; Europe Innovation; Siparex Ventures; AGF Private Equity; 123 Multinova; CDC IXIS Innovation; Auriga Partners; Sudinnova; and Natexis...
08:00 , Dec 9, 2002 |  BioCentury  |  Finance

Ebb & Flow

The preferred currency for biotech M&A has been stock rather than cash, because most CEOs want to keep the latter to fund R&D. Thus, it's notable that Triangle (VIRS) is the third Warburg Pincus portfolio...
08:00 , Dec 5, 2002 |  BC Extra  |  Top Story

Targacept raises $46 million

Neurological play Targacept (Winston-Salem, N.C.) raised $46 million in a second round of financing led by Nomura International's Healthcare Private Equity Group. Other investors included New Enterprise Associates; CDIB BioScience Ventures; Easton Hunt Capital Partners;...
07:00 , Jul 29, 2002 |  BioCentury  |  Finance

Ebb & Flow

Amgen's blockbuster second quarter earnings were driven by its homegrown products. In contrast, Enbrel, the rheumatoid arthritis drug acquired in the merger with Immunex , continued to have manufacturing problems that are leading patients to...